Moody Aldrich Partners LLC Raises Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

Moody Aldrich Partners LLC raised its position in Wave Life Sciences Ltd. (NASDAQ:WVE) by 31.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 398,475 shares of the company’s stock after purchasing an additional 95,413 shares during the period. Moody Aldrich Partners LLC’s holdings in Wave Life Sciences were worth $4,929,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of WVE. Maverick Capital Ltd. lifted its position in Wave Life Sciences by 31.0% during the third quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company’s stock valued at $82,390,000 after acquiring an additional 2,378,159 shares during the last quarter. FMR LLC lifted its holdings in shares of Wave Life Sciences by 174.5% in the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company’s stock valued at $12,630,000 after buying an additional 979,110 shares during the period. RTW Investments LP acquired a new position in Wave Life Sciences in the 3rd quarter worth about $7,380,000. Maven Securities LTD purchased a new position in Wave Life Sciences during the third quarter valued at $6,970,000. Finally, Walleye Capital LLC purchased a new position in shares of Wave Life Sciences in the third quarter worth about $4,940,000. Institutional investors own 89.73% of the company’s stock.

Analysts Set New Price Targets

WVE has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a research note on Wednesday, November 13th. B. Riley raised their target price on Wave Life Sciences from $19.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Truist Financial upped their target price on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, November 12th. Royal Bank of Canada lifted their price target on shares of Wave Life Sciences from $7.00 to $15.00 and gave the stock a “sector perform” rating in a research note on Monday, October 21st. Finally, Mizuho raised their price objective on Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $22.22.

Insider Transactions at Wave Life Sciences

In other news, insider Chris Francis sold 36,000 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $576,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paul Bolno sold 50,000 shares of Wave Life Sciences stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the completion of the transaction, the chief executive officer now directly owns 217,351 shares of the company’s stock, valued at approximately $3,260,265. This trade represents a 18.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 137,234 shares of company stock valued at $2,059,671 in the last ninety days. 29.10% of the stock is currently owned by corporate insiders.

Wave Life Sciences Trading Down 1.3 %

Shares of NASDAQ WVE opened at $12.04 on Wednesday. Wave Life Sciences Ltd. has a 12-month low of $3.50 and a 12-month high of $16.74. The firm’s 50-day simple moving average is $13.26 and its 200 day simple moving average is $10.29.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.